To ask the Scottish Government for what reason it took a year longer for sparsentan and Kinpeygo to be approved for use by NHS Scotland in the treatment of kidney disease than it did for them to be approved for use in England. (S7O-00256)
I declare an interest as an employee of the national health service.
Alison ThewlissSNPThe Minister for Community Care · Glasgow Central
The Scottish Medicines Consortium and the National Institute for Health and Care Excellence are separate health technology assessment bodies that use different appraisal processes, methodologies and timetables. As a result, medicines may be assessed at different times across the United Kingdom. Furthermore, pharmaceutical companies determine when to submit medicines for assessment.
In the case of sparsentan, I understand that the company submitted evidence to NICE in September 2024, but did not submit evidence to the SMC until June 2025. The different submission dates, alongside separate appraisal processes, contributed to the different decision timetables.
I thank the minister for the detailed answer. She will be aware that the delay forced Scottish patients to wait significantly longer than those in England, causing needless suffering and further complications with their condition, including the potential need for a transplant. Does she agree that it is yet another example of an unnecessary duplication of services by the Scottish Medicines Consortium? Will she acknowledge that the delay demonstrates how Scottish patients are losing out on the potential union dividend of a single, efficient regulatory system?
I appreciate that, for everybody who is waiting for a particular medicine to be approved, any wait can feel too long. However, if the member is arguing for the SMC to be abolished, I am afraid that I cannot agree with him.
I recognise that we have a strong and efficient route in Scotland for licensed medicines to be appraised through the Scottish Medicines Consortium. Can the minister speak more about how the process works and how medication approval rates can differ throughout devolved nations as a result?
The regulation for the licensing, safety and efficacy of medicines is reserved to the UK Government and is the responsibility of the UK-wide Medicines and Healthcare products Regulatory Agency. Following the UK-wide reserved medicines licensing process, health technology assessment decisions made in the UK are devolved. In Scotland, HTA decisions are made by the Scottish Medicines Consortium and, in England, they are made by NICE. NICE and the SMC are independent organisations with distinct HTA arrangements, evidence requirements, and timetables. Therefore, it is not unusual for decisions to be reached at different times across the UK, which can sometimes benefit patients in Scotland.
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.